Chugai Opens U.S. Hub in NJ

Chugai Pharma USA Inc. (CPUSA), a wholly-owned subsidiary of Chugai Pharmaceutical Co, Ltd. headquartered in Tokyo, has opened its new office in Berkeley Heights, NJ, dedicated to translational clinical research.

CPUSA is now focused on Early Development and, in spring of this year established Chugai’s Translational Clinical Research Division (TCRD). TCRD is Chugai’s first global organization composed of functions in Japan, Europe, and the U.S. (CPUSA), dedicated to late preclinical and early clinical development of Chugai-originated pipeline products. It aims to accelerate the proof-of-concept process by bringing translational research-powered medicines to development stage as efficiently as possible. 
 
“CPUSA is further evidence of Chugai’s commitment to and belief in the potential of translational research to use best-in-class drug discovery techniques in the development of transformative, patient-focused therapies that fulfill unmet needs and improve patients’ lives across the world,” Osamu Nagayama, chairman and chief executive officer of Chugai.   
 
“New Jersey’s standing as a key market for pharmaceutical innovation will aid in the growth of our U.S. talent and operations, which will in turn support and further strengthen our pipeline of novel therapies designed to fulfill unmet needs and improve patients’ lives across the world,” said Norihisa Onozawa, president and chief executive officer of CPUSA. “Our team is proud to contribute to Chugai’s global work by inspiring and guiding its therapeutic development efforts to achieve new heights.”
 
Chugai focuses on treatments in oncology, bone and joint diseases, renal diseases, and autoimmune diseases. Chugai has a strategic alliance with Roche, leveraging its resources to pursue biopharmaceutical, antibody, and molecular-targeted research technologies, as well as chemical synthesis technology.